Advertisement
U.S. markets open in 1 hour 52 minutes

DBV Technologies S.A. (DBV.PA)

Paris - Paris Delayed Price. Currency in EUR
1.3480-0.0120 (-0.88%)
As of 12:02PM CET. Market open.
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close1.3600
Open1.3500
BidN/A x N/A
AskN/A x N/A
Day's Range1.3390 - 1.3500
52 Week Range1.0950 - 4.3000
Volume11,145
Avg. Volume151,426
Market Cap131.787M
Beta (5Y Monthly)0.80
PE Ratio (TTM)N/A
EPS (TTM)-0.7000
Earnings DateMar 07, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.46
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for DBV.PA

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Insider Monkey

      DBV Technologies S.A. (NASDAQ:DBVT) Q4 2023 Earnings Call Transcript

      DBV Technologies S.A. (NASDAQ:DBVT) Q4 2023 Earnings Call Transcript March 7, 2024 DBV Technologies S.A. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Apologies for the late start of our conference. Welcome to the DBV Full Year 2023 Financial Results […]

    • GlobeNewswire

      DBV Technologies announces filing of 2023 Annual Report on Form 10-K and Universal Registration Document

      Montrouge, France, March 8, 2024 DBV Technologies announces filing of 2023 Annual Report on Form 10-K and Universal Registration Document DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need (the “Company”), today announced the filing, for the year ended December 31, 2023, of its Annual Report on Form 10-K wi

    • GlobeNewswire

      DBV Technologies Reports Full Year 2023 Financial Results and Business Update

      Montrouge, France, March 7, 2024 DBV Technologies Reports Full Year 2023 Financial Results and Business Update Advanced Viaskin™ Peanut clinical development programs in peanut-allergic toddlers (1 through 3 years old) and children (4 through 7 years old)Strengthened executive leadership team in preparation for BLA submissionReported cash and cash equivalents of $141 million DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical compa